News
How some COVID-19 vaccines could cause rare blood clots
April 14, 2021
Six cases of a rare but serious event in patients who got the J&J vaccine are being reviewed.
News
Novel antiplatelet drug: Hope for efficacy without bleeding?
April 12, 2021
A new antiplatelet drug with a completely novel mechanism of action could hold the promise of delivering the holy grail – reducing cardiac events without increasing bleeding.
![1]()
News
DAPT increases bleeding without decreasing mortality in patients with coronary disease and diabetes
February 2, 2021
In patients who have diabetes with known coronary disease but without prior MI or stroke, what is the effect of dual-antiplatelet therapy (DAPT) with aspirin and ticagrelor on cardiovascular outcomes and bleeding events?
![1]()
News
Anticoagulation and antiplatelet therapy after GI bleed cut mortality, ischemic events
January 28, 2021
In patients who present with a gastrointestinal bleed (GIB) while on an anticoagulants (AC) or antiplatelets (AP), what are the risks and benefits to resuming these medications?
News
Doctors search for missing link between COVID-19 and ITP
January 28, 2021
“We don’t know much about platelet counts in COVID-19 at all.”
News
Full-dose anticoagulation reduces need for life support in COVID-19
January 25, 2021
“We have treatments that are improving outcomes but not as many that reduce mortality, so we’re hopeful when the full dataset comes in that will be confirmed.”
![1]()
News
DOACs show safety benefit in early stages of CKD
January 15, 2021
In terms of efficacy and bleeding risk, what is known about anticoagulation in patients with chronically impaired renal function?
News
In COVID-19 patients, risk of bleeding rivals risk of thromboembolism
January 12, 2021
Trials are urgently needed to define optimal anticoagulation strategies for COVID-19 infection.
News
A 4-point thrombocytopenia score was found able to rule out suspected HIT
January 11, 2021
A low score – 3 points or less – has a negative predictive value of 99.8%, “so HIT is basically ruled out.”
News
Cost is the main hurdle to broad use of caplacizumab for TTP
December 7, 2020
“If we take finances out, I think almost every patient except those with a bleeding risk or bleeding problem should get it,” an investigator said.
